- Keywords > antibacterial resistance (ABR)
- Keywords > antibiotic resistance
- Keywords > antimicrobial resistance (AMR)
- Keywords > antimicrobial resistance surveillance
- Keywords > containment of antimicrobial resistance
- Keywords > new medicines
- Keywords > pharmaceutical research and development (R&D)
- Keywords > pharmacist - surveillance of the safe use of medicines
- Keywords > surveillance - antibiotic resistance and antibiotic use
- Keywords > confinement antimicrobien
(2017; 238 pages)
AURA 2017: Second Australian report on antimicrobial use and resistance in human health provides data and analysis from the Antimicrobial Use and Resistance in Australia (AURA) Surveillance System, primarily from 2015.
AURA 2017 includes data about organisms that have been determined to be a priority for Australia, the volume of antimicrobial use (AU), the appropriateness of antimicrobial prescribing, key emerging issues for antimicrobial resistance (AMR), and a comparison of Australia’s situation with other countries.
This second AURA report provides an expanded view of AMR, AU and appropriateness of prescribing in Australia. Participation in the AURA Surveillance System by both public and private healthcare providers has grown, and the increased volume of data has greatly contributed to the capacity to use the AURA Surveillance System to identify emerging issues and monitor trends. AURA now includes the National Alert System for Critical Antimicrobial Resistances (CARAlert), which allows the early detection of critical antimicrobial resistances and, over time, will provide information on the effectiveness of measures to promote appropriate AU and contain AMR.